Literature DB >> 9340840

[Value of adjuvant progestagen therapy in patients with endometrial carcinoma].

W Renner, A Atzinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9340840     DOI： 10.1007/bf03038189

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials.

Authors:  P L Martin-Hirsch; R J Lilford; G J Jarvis
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1996-04       Impact factor: 2.435

2.  [Current status of drug treatment of endometrial carcinoma].

Authors:  K D Schulz; R Kaiser
Journal:  Gynakologe       Date:  1983-06

3.  A randomized trial of adjuvant progestagen in early endometrial cancer.

Authors:  I Vergote; K Kjørstad; V Abeler; P Kolstad
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860

Review 4.  [Therapy of endometrial cancer].

Authors:  A Pfleiderer
Journal:  Geburtshilfe Frauenheilkd       Date:  1991-10       Impact factor: 2.915
  4 in total
  1 in total

1.  Studies on the role of osteopontin-1 in endometrial cancer cell lines.

Authors:  J C Hahne; S R Meyer; P Kranke; J Dietl; M Guckenberger; B Polat; A Hönig
Journal:  Strahlenther Onkol       Date:  2013-10-16       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.